Nigella seed

Synopsis

Nigella Seed (Nigella sativa L.)

1. Identity, Nomenclature, and Natural Source

Nigella sativa, which belongs to the botanical family Ranunculaceae, is a widely used medicinal plant found throughout the world. It is an annual herb of the Ranunculaceae family, native to southern Europe, North Africa, south and southwest Asia, and has been traditionally used since ancient times as an important medicinal plant and spice.

Nigella sativa is a plant that grows to a height of 20–30 cm and has linear leaves, with flowers colored light blue and white, which form a fruit in the form of a large, swollen capsule with three to seven connected follicles containing the seeds. The major Nigella seed producers are India, Pakistan, Syria, Turkey, Saudi Arabia, Egypt, and Bangladesh.

The seeds are sold and discussed under numerous common names across different cultures and languages. These include:

Black seed or black cumin — the most widely used English names
Kalonji — used across South Asia (India, Pakistan, Bangladesh)
Habbatus sauda or Habbat al-Barakah ("the blessed seed") — Arabic names
Black caraway — a common name in Western food contexts
Fennel flower — occasionally used in historical European botany

The whole or ground seeds of Nigella sativa L., known in Western culture as "black cumin" or "black caraway," has a three-millennial history of use in Middle- and Far-Eastern cultures as a food ingredient.

Common Forms and Preparations

The seeds are commercially available in several forms:

Whole seeds — used directly as a culinary spice or chewed
Cold-pressed or solvent-extracted fixed oil — marketed as "black seed oil" or "black cumin seed oil"
Ground seed powder — encapsulated for supplemental use
Aqueous or ethanolic extracts — used in research and some traditional preparations
Topical preparations — creams, gels, and diluted oils applied to the skin

In some cultures, the black seeds are used to flavor bread products, and are used as part of the spice mixture panch phoron (meaning a mixture of five spices) and alone in many recipes in Bengali cuisine and most recognizably in naan.

2. Traditional and Historical Use

Ancient Civilizations

N. sativa is one of the most ancient known domesticated plants and its seeds were reportedly found in Tutankhamun's tomb. Black cumin is referred to by its Hebrew name "Ketzah" in the Bible in the book of Isaiah 28:25–27 and known for its curative properties.

In ancient Babylonia the plant was used externally to treat swelling, the hair, and bruises, and internally to cure stomach problems. Classical physicians such as Hippocrates and Galen described the use of black cumin to treat various maladies, including infections in the nose, while Dioscorides described the plant and its black seeds with their pungent smell, and reported their use as food and for curative purposes to treat headaches and toothache, to cure diseases of the eyes and skin and leprosy, to eliminate intestinal worms, to accelerate menstruation, to increase urine flow and milk flow, and to repel snakes.

Islamic and Middle Eastern Traditions

Nigella sativa or "black seed" is a standard feature in traditional medicine of the Islamic world. Abu Hurayra quoted Muhammad saying: "Utilize the black seed for without a doubt, it is a cure for all sicknesses aside from death." (Hadith Al-Bukhari 7:591)

The Persian physician and philosopher Ibn Sina, commonly known in the West as Avicenna, mentioned N. sativa in his famous medical treatise "Canon of Medicine," which is considered a hallmark in the history of human medicine and was used as the main medical text until the 17th century in Europe. In his writings, he stated that N. sativa has preventative and restorative features as it stimulates the body's energy and helps in recovery from fatigue or dispiritedness.

In Indian and Middle Eastern traditional medicine systems, including Unani and Ayurveda, N. sativa L. seeds and their oil have been used for centuries both as a dietary component and a therapeutic agent. In Islamic tradition, its medicinal value is emphasized in Prophetic Medicine, where it is described as a remedy for a wide range of ailments, contributing to its continued use and reverence among Muslim communities.

South and East Asian Traditions

Black cumin was traditionally used as a preservative in mummification in the ancient Egyptian civilization, and it has a long history of use as medicine in the Indian traditional medicine system like Unani and Ayurveda. Black seed was widely used in such traditions as Unani, Ayurveda, and Siddha. Called "kalonji," black seeds are used in Ayurveda primarily for digestive and respiratory support. Traditional Ayurvedic formulations often combine black seeds with other herbs and spices to address specific imbalances.

The plant is recognized for its therapeutic potential in the Unani system of medicine, where it is traditionally employed in the management of various disorders, particularly those related to the digestive, respiratory, and metabolic systems.

Traditional Indications Across Cultures

Across these traditions, N. sativa was employed for an extensive range of purposes. Classical physicians reported its use to treat headaches and toothache, to cure diseases of the eyes and skin and leprosy, to eliminate intestinal worms, to accelerate menstruation, to increase urine flow and milk flow, and to repel snakes. The physician Assaf additionally set out medical uses, for example, to treat colds in the head, chest and body, to kill intestinal worms, to increase semen and increase virility, to cure leprosy, bright skin spots, infections in the nose, and to enrich hair growth. In the Arab tradition, black seed has long been used to treat such ailments as asthma, flatulence, polio, kidney stones, abdominal pain, and so on.

3. Chemical Composition and Key Constituents

Fixed Oil

Black cumin seed contains fixed oil (35.6–41.6%). Besides the high oil content, black cumin seed oil (BCSO) is rich in essential fatty acids, as well as bioactive sterols and tocols with functional properties. The fatty acid profile is dominated by unsaturated fatty acids, especially polyunsaturated fatty acids (59.7%), followed by monounsaturated fatty acids (24.1%), and saturated fatty acids (16.1%). The major polyunsaturated fatty acid is linoleic acid, which comprises approximately half of the fatty acid composition, while oleic acid is the main monounsaturated one (24.1%).

Data from Iranian seed samples confirm this profile: the main fatty acids of the fixed oil were linoleic acid (55.6%), oleic acid (23.4%), and palmitic acid (12.5%). As for the tocols profile, BCSO contains a high level of β-tocotrienol (1,195 mg/kg) and γ-tocopherol isomer (208 mg/kg). β-Sitosterol is the dominant sterol compound from the unsaponifiable fraction of BCSO (1,135–1,182 μg/g oil).

Volatile (Essential) Oil and Key Bioactive Compounds

Seed volatiles consist largely of olefinic and oxygenated monoterpenes, mainly p-cymene, thymohydroquinone, thymoquinone, γ-terpinene, and α-thujene, with lower levels of sesquiterpenes, mainly longifolene.

The essential oil is dominated by thymoquinone, which varies considerably by geographic origin and method of extraction. The essential oil of Nigella sativa includes thymoquinone (10–70%), p-cymene (1–20%), carvacrol (1–20%), trans-anethole (0.1–5%), p-terpineol (1–10%), and longifolene (0.5–10%), each based on a total volume of the essential oil.

The active metabolites isolated from nigella include thymoquinone (TQ), dithymoquinone, thymohydroquinone, carvacrol, p-cymene, trans-anethole, terpineol, pinene, sesquiterpene longifolene, and thymol, with isoquinoline alkaloids and indazole or pyrazol alkaloids, including nigellicine and nigellidine, present in trace levels.

Importantly, quantitative analysis of the seed (especially the volatile fraction) yields widely variable results, which may be due to one or a combination of different crop origins or possible varietal differences, contamination/adulteration, method of extraction, stage of maturation of the extracted seed, and other factors. This chemical variability has important implications for standardization of supplements and interpretation of clinical study results.

Thymoquinone: The Principal Bioactive Constituent

Thymoquinone, a monoterpene molecule, is chemically known as 2-methyl-5-isopropyl-1,4-benzoquinone. It is abundantly present in seeds of Nigella sativa L. that is popularly known as black cumin or black seed and belongs to the family Ranunculaceae. A large number of studies have revealed that thymoquinone is the major active constituent in N. sativa oil, and this constituent is responsible for the majority of the pharmacological properties.

Thymoquinone has been reported to possess potent lipophilicity and limited bioavailability and exhibits light and heat sensitivity. The thymoquinone content in commercial black seed oils varied from 3.08 to 809.4 mg/100 g (mean) across products analyzed. This enormous variability underscores the challenge in standardizing and comparing clinical outcomes between studies using different product sources.

4. Mechanisms of Action

Anti-Inflammatory Pathways

Thymoquinone (TQ), a monoterpene molecule present in Nigella sativa L., has anti-inflammatory, anti-oxidant, and anti-apoptotic properties in several disorders such as asthma, hypertension, diabetes, inflammation, bronchitis, headache, eczema, fever, dizziness, and influenza. TQ exerts its anti-inflammatory and anti-oxidant effects via several molecular pathways, including the release of cytokines, and activation of cyclooxygenase-2 (COX-2), nuclear factor erythroid 2–related factor 2 (Nrf2), phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).

Thymoquinone's capacity to suppress TPA-induced COX-2 expression and NF-κB activation, along with its ability to stimulate the expression of cytoprotective proteins, forms the mechanistic foundation for its anti-inflammatory and antioxidative effects. Thymoquinone has been shown to reduce pro-inflammatory mediators in inflamed tissue, including IL-1, TNF-α, IL-6, MCP-1, C-reactive protein, myeloperoxidase, and NF-κB.

Antioxidant Activity

N. sativa extract increases the activity of antioxidant enzymes (catalase, glutathione peroxidase, and glutathione-S-transferase) and acts as a free radical scavenger. TQ has an antioxidant role, improves the body's defense system, induces apoptosis, and controls the Akt pathway.

Immunomodulatory Effects

N. sativa suppresses inflammatory mediators, leukotrienes, prostaglandins, and B cell-mediated immune response while balancing Th1/Th2 responses and potentiating T cell and natural killer cell-mediated immune responses, as an anti-inflammatory and immunomodulatory agent. Immune system modulation is one of the most important properties of N. sativa, and a number of studies have been done in order to prove this significant effect.

Anticancer Mechanisms (Preclinical)

As an anti-cancer agent, its effects such as modulation of the activities of molecular targets including p53, p73, PTEN, STAT3, PPAR-γ, activation of caspases, and generation of ROS have been demonstrated.

Note on Synergy

Research on human pre-adipocytes suggests that thymoquinone alone, at certain concentrations, is not able to control IL-6 release, but its high content, together with the other components of N. sativa oil, works synergistically to control the release of this interleukin. IL-1β is also modulated more by the other components of N. sativa oil than by thymoquinone alone. This finding highlights that the whole extract may produce different effects than isolated TQ alone.

5. Scientific Evidence by Health Area

5.1 Glycemic Control and Type 2 Diabetes

This is the area with the most robust body of human clinical evidence for N. sativa. Seven trials were included in one meta-analysis of glycemic and serum lipid profile endpoints. Supplementation with N. sativa significantly improved fasting blood sugar (FBS) [−17.84 mg/dl, 95% CI: −21.19 to −14.49, p<0.001], HbA1c [−0.71%, 95% CI: −1.04 to −0.39, p<0.001], total-cholesterol (TC) [WMD: −22.99 mg/dl, 95% CI: −32.16 to −13.83, p<0.001], and LDL-cholesterol.

A specific clinical trial in type 2 diabetic patients used varying doses. In a study by Bamosa et al., patients with type 2 diabetes mellitus were randomly divided into three groups to receive Nigella sativa seed extracts at 1 g, 2 g, and 3 g per day respectively for 12 weeks. Generally, the three doses of Nigella sativa were well tolerated, with only three patients who experienced a mild epigastric discomfort that settled down after taking the capsules post meals.

Taking Nigella seed powder at a dose of 1 g twice daily for 3 to 12 months improves glycated hemoglobin (HbA1c) and reduces fasting blood glucose compared to baseline in diabetic patients already taking antidiabetic medications. Improvements in pancreatic beta-cell function and insulin resistance have also been reported after 12 weeks of treatment.

Evidence strength: Moderate, based on multiple small-to-medium RCTs and meta-analyses. Trials generally show consistent direction of benefit on fasting glucose and HbA1c; however, study populations, doses, and durations are heterogeneous. Larger, better-powered RCTs are still needed.

5.2 Lipid Profile and Cardiovascular Markers

A systematic review and meta-analysis of RCTs found a significant reduction in total cholesterol (WMD: −16.80; 95% CI: −21.04, −12.55), triglycerides (WMD: −15.73; 95% CI: −20.77, −10.69), and LDL-cholesterol (WMD: −18.45; 95% CI: −22.44, −14.94).

A large comprehensive meta-analysis (82 RCTs) reported that N. sativa supplementation significantly improved body fat percentage, body mass index, skeletal muscle mass, waist circumference, weight, waist-to-hip ratio, diastolic blood pressure, systolic blood pressure, mean arterial pressure, fasting blood sugar, hemoglobin A1c, postprandial blood glucose, C-reactive protein, high-sensitivity CRP, interleukin-6, TNF-α, HDL-cholesterol, LDL-cholesterol, total cholesterol, triglycerides, as well as markers of liver and kidney function and oxidative stress.

Regarding blood pressure specifically, Nigella sativa consumption showed a higher impact on reducing systolic blood pressure (SBP) than diastolic blood pressure (DBP) levels. In addition, the consumption of N. sativa oil was more effective in lowering blood pressure levels than N. sativa powder.

A separate systematic review focused on metabolic syndrome noted that Nigella sativa has proved to have a significant positive effect on lipid profile and glycaemic index. The results for blood pressure and anthropometric indices are less convincing, as results were inconsistent across studies.

Evidence strength: Moderate for lipid improvements; weaker and more inconsistent for blood pressure and body composition. Heterogeneity of preparations, doses, and patient populations limit firm conclusions. Despite considerable use of N. sativa in traditional medicine practices in Africa and Asia, there is insufficient high-quality clinical evidence to indicate that consuming the seeds or oil provides any benefit to human health. This assessment by GBIF reflects the need for larger, independently replicated trials.

5.3 Respiratory Conditions: Asthma and Allergic Rhinitis

N. sativa oil improved symptom control and decreased blood eosinophilia in children and adults with asthma, and it also reduced the symptoms of allergic rhinitis in clinical investigations.

One RCT examined the effect of N. sativa supplementation on asthma. In a single-blind, placebo-controlled, randomized study conducted at an asthma and allergy clinic of a university hospital in eastern Saudi Arabia, patients were divided into three groups. A control group (n=24) received placebo, while NS-1 and NS-2 groups (n=26 each) received 1 and 2 g/day of N. sativa, respectively, for 3 months along with maintenance inhaled therapy.

For allergic rhinitis (AR), a 2024 meta-analysis of RCTs concluded that the observation group demonstrated relative safety and had an enhanced effect on allergic rhinitis treatment and total nasal symptom improvement compared to the control group. However, the authors noted that the inclusion of fewer studies and the lower quality of trial design might affect the stability of the results.

All reviewed studies demonstrated that supplementation or treating patients with N. sativa seed (25–250 mg/kg/day) or oil (25 µL–0.5 mL/day) for 15–30 days alleviates symptoms of allergic rhinitis and decreases the body temperature in allergic patients.

The mechanistic basis in animal and in vitro models includes that N. sativa and its constituents attenuated allergic airway inflammation in animal models of allergic disorders; these effects may be mediated through inhibiting pro-inflammatory cytokines, such as TNF-α, IL-4, IL-5, IL-13, and IL-1β, and down-regulation of PGD2 and COX-2 expression, as well as reduction of airway inflammatory cell infiltration.

Evidence strength: Preliminary to moderate for respiratory and atopic conditions. Results across small RCTs are generally positive for symptom reduction, but trials are small, of short duration, and methodologically heterogeneous. There is still a need for larger, well-designed studies.

5.4 Rheumatoid Arthritis and Inflammatory Joint Conditions

In a small pre- and post-rheumatoid arthritis study (N = 40), adjuvant N. sativa oil 500 mg twice daily resulted in improved disease activity scores after 1 month, using the disease activity score (DAS28), European League Against Rheumatism response criteria, and American College of Rheumatology 20 responder index. In patients with primary osteoarthritis of the knee, however, a 12-week oral dose of powdered N. sativa seeds (2 g/day) did not provide a significant improvement in overall pain or function scores compared to controls.

Evidence strength: Very preliminary. The small number of trials, small sample sizes, and lack of replication mean no firm conclusions can be drawn for joint disorders.

5.5 Skin Conditions

In a psoriasis study, the percent reduction in Psoriasis Area and Severity Index scores were significantly reduced in all three treatment groups at 8 and 12 weeks, with the greatest percent reduction occurring with combination therapy (74.6%) at 12 weeks. Patients receiving Nigella therapy or combination therapy experienced significantly improved oxidative stress parameters and rates of relapse (33.3% or 27.8%, respectively). In contrast, those receiving methotrexate therapy alone had a significant increase in oxidative stress and a relapse rate of 56.3%.

Due to its numerous important ingredients it was found that it affects different areas of the body and has many pharmacological effects including antibacterial, antiviral, anti-inflammatory, and wound-healing effects and also for acne vulgaris, skin cancer, pigmentation, and many cosmeceutical applications.

Evidence strength: Mostly preliminary. Individual trials show promising signals for skin conditions including acne and psoriasis, but the evidence base is thin and studies are generally small and short-term.

5.6 Gastrointestinal Effects

Several studies demonstrated that N. sativa has anti-cancer, hepatoprotective, anti-bacterial, anti-schistosomiasis, anti-inflammatory, and antioxidant activities in the gastrointestinal system.

Clinical research shows that in patients receiving quadruple therapy for H. pylori consisting of metronidazole, amoxicillin, bismuth subcitrate, and omeprazole, eradication occurred in 88% of patients receiving the quadruple therapy plus Nigella seed powder at a dose of 1 gram twice daily for 8 weeks, versus 55% of patients receiving the quadruple therapy alone.

Evidence strength: Very preliminary for most gastrointestinal applications. The H. pylori data from a single small trial are intriguing but not yet replicated at scale.

5.7 Immune Modulation

Black seed and TQ have shown multiple useful effects for the treatment of patients with several diseases, such as inflammatory and auto-immune disorders, as well as metabolic syndrome. In clinical studies reviewed comprehensively, immune system modulation is one of the most important properties of N. sativa, and a number of studies have been done in order to prove this significant effect.

Evidence strength: Largely preclinical (animal and in vitro). Limited direct human evidence for discrete immunological endpoints.

5.8 Cancer (Anticancer Activity)

The protective effects of this plant and its main constituent in different tissues including brain, heart, liver, kidney, and lung have been proved against some toxic agents either natural or chemical toxins in animal studies. Several in vitro and animal studies in scientific databases investigate the protective effects of N. sativa and its main constituents; however, human reports are rare, and further studies are required to determine the efficacy of this plant as a protective agent in human intoxication.

Evidence strength: Preclinical only for direct anticancer use. In vitro and animal model data exist for various cancer cell lines, but there are no established clinical trials supporting N. sativa or TQ as a cancer treatment in humans. While recent reports on the anti-inflammatory efficacy of TQ in various disease states are summarized in the literature, further investigation is necessary to better characterize the efficacy of TQ as a therapeutic agent.

5.9 Thyroid Function

In a clinical trial, patients who took 2 grams of powdered Nigella sativa daily for 8 weeks experienced an average drop in TSH levels by about 2.0 mIU/l. Most studies used a dose of 2 grams of powdered Nigella sativa daily, typically divided into two 1-gram doses taken before lunch and dinner. While most studies used powdered Nigella sativa, some sources suggest that a daily dose of 1,000 mg of high-quality black seed oil may also be effective. While the current research on Nigella sativa for thyroid disorders is promising, there are several limitations to consider: most studies were conducted over relatively short periods (8 weeks). Longer-term studies will be able to assess the sustained benefits and safety of Nigella sativa supplementation. Many of the studies had relatively small sample sizes.

Evidence strength: Very preliminary. Very few small trials with short durations. Not yet sufficient to support clinical recommendations.

6. Body Systems Associated with Nigella Sativa

Various studies on N. sativa have been carried out and a broad spectrum of its pharmacological actions have been established, which include antioxidant, antidiabetic, anticancer, antitussive, immunomodulator, analgesic, antimicrobial, anti-inflammatory, spasmolytic, and bronchodilator activities.

Based on the accumulated clinical and preclinical literature, N. sativa is associated with the following body systems:

Metabolic and endocrine system: blood glucose regulation, lipid metabolism, insulin sensitivity, thyroid function
Cardiovascular system: blood pressure modulation, lipid-lowering, anti-atherogenic effects
Respiratory and immune system: bronchodilation, anti-allergic, antitussive activity
Gastrointestinal system: gastroprotective, antispasmodic, anti-H. pylori activity
Hepatic and renal systems: hepatoprotective and nephroprotective effects (primarily preclinical)
Integumentary system (skin): wound healing, acne, psoriasis, anti-inflammatory topical use
Musculoskeletal system: anti-inflammatory effects studied in rheumatoid arthritis models
Neurological system: early preclinical evidence for neuroprotection, memory, and analgesic effects

7. Dosage Forms and Dosages Reported in Studies

Black seed is typically taken in the form of an oil or a ground powder, taken orally at a dosage of 1 to 3 grams daily. A wide range of specific dosages have been used across published human clinical trials:

Seed powder/capsules — diabetes: Patients with type 2 diabetes mellitus received Nigella sativa seed extracts at 1 g, 2 g, and 3 g per day for 12 weeks.
Seed powder/capsules — type 2 diabetes, one-year study: Nigella sativa seeds were provided in the form of 500 mg oral capsules. A dose of 2 grams/day was used. The supplementation in two divided doses daily, along with the regular standardized treatment, continued for one year.
Seed/oil — partly controlled asthma: Patients received 1 g/day or 2 g/day of N. sativa for 3 months along with maintenance inhaled therapy.
Oil softgel capsules — chronic disease/obesity: The intervention group received 3 g/day NS oil soft gel capsules (one capsule, three times a day, 30 minutes before each main meal) for eight weeks.
Oil — Behçet's disease: Treatment and control groups received soft gels containing 1,000 mg NS oil or 1,000 mg placebo per day for 12 months.
Metabolic syndrome (general range): Doses of 100 mg of N. sativa extract, 5 mL of oil, and 1.5 to 3 g of powder daily over periods of up to 3 months have been used in metabolic syndrome.
Allergic rhinitis studies: Supplementation with N. sativa seed (25–250 mg/kg/day) or oil (25 µL–0.5 mL/day) for 15–30 days has been studied.
Thymoquinone content guidance: A dose of 4 mL of oil per day from a high-TQ commercial product contains approximately 30 mg TQ, which is unlikely to be harmful. Based on the literature, a safe daily TQ dosage appears to be less than 48.6 mg per adult.

8. Safety Considerations and Interactions

General Safety Profile

Clinical trials that examined N. sativa and its active constituent, thymoquinone, found these agents safe, but notably several adverse effects such as bloating, nausea, and burning sensation were observed in functionally dyspeptic patients treated with N. sativa oil.

In a clinical study, administration of N. sativa oil at 5 mL/day for 26 days produced no significant hepatic, renal, or gastrointestinal adverse effects in healthy volunteers. Similarly, daily intake of N. sativa seeds at 3 g/day for 3 months in 39 centrally obese subjects did not result in notable side effects.

Toxicological assessments indicate a wide therapeutic margin and minimal adverse effects at traditional doses (1–3 g/day seeds or 5 mL/day oil).

Toxicological Data

LD50 for administered N. sativa seed fixed oil varied from 28.8 mL/kg to 3,371 mg/kg in mice, while 21 g/kg of aqueous, methanol, and chloroform extracts of N. sativa did not lead to any mortality. Subacute toxicity evaluations indicated that aqueous, methanol, and chloroform extracts of N. sativa at doses as high as 6 g/kg do not produce toxicity. Investigation of chronic toxicity found that 2 mL/kg of N. sativa fixed oil is slightly toxic.

Adverse Effects Reported in Clinical Studies

In addition to the beneficial effect of N. sativa, minor adverse effects, such as nasal dryness and itching, were noted during allergic rhinitis trials, but they were temporary and statistically insignificant. Published studies on human and animal models have shown that administration of N. sativa produced no significant hepatic, renal, or gastrointestinal adverse effects, or any other marked side effects, other than few reported cases of allergic contact dermatitis.

Drug Interactions

N. sativa may interact pharmacokinetically with concomitantly administered drugs, as the extracts of N. sativa have shown inhibition of cytochrome P-450 (CYP) 3A4/5/7 and 2C9-mediated metabolism of substrates in in vitro studies. This inhibition is pharmacologically significant because CYP3A4 and CYP2C9 are responsible for the metabolism of a large number of clinically used drugs.

Thymoquinone competitively inhibits the enzyme that metabolizes warfarin, which could cause warfarin to build up in the system and increase bleeding risk. Research suggests that more than 1 gram per day of black seed or black seed oil could be enough to alter warfarin's behavior in the body. Thymoquinone can increase blood levels of glibenclamide (a common oral diabetes medication) by slowing the enzymes that break it down. It similarly affects the metabolism of tolbutamide and phenytoin (an anti-seizure medication), all through inhibition of the same liver enzyme family.

Challenges: Standardization and Quality Variability

Challenges persist regarding phytochemical variability, absence of standardized formulations, and insufficient large-scale clinical trials. The variability in thymoquinone content across commercial products — documented to range by orders of magnitude — means that the dose of TQ actually delivered to a consumer from a labeled dose of oil or powder may differ substantially from that used in any given clinical study.